Any procedure in which blood is withdrawn from a donor, a portion is separated and retained and the remainder is returned to the donor.
The transfer of blood components such as erythrocytes, leukocytes, platelets, and plasma from a donor to a recipient or back to the donor. This process differs from the procedures undertaken in PLASMAPHERESIS and types of CYTAPHERESIS; (PLATELETPHERESIS and LEUKAPHERESIS) where, following the removal of plasma or the specific cell components, the remainder is transfused back to the donor.
Centers for collecting, characterizing and storing human blood.
The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed)
The transfer of blood platelets from a donor to a recipient or reinfusion to the donor.
'Blood donors' are individuals who voluntarily and safely donate a specific amount of their own blood, which can be further separated into components, to be used for transfusion purposes or for manufacturing medical products, without receiving remuneration that is intended to reward them financially.
The transfer of erythrocytes from a donor to a recipient or reinfusion to the donor.
The removal of LEUKOCYTES from BLOOD to reduce BLOOD TRANSFUSION reactions and lower the chance of transmitting VIRUSES. This may be performed by FILTRATION or by CYTAPHERESIS.
The residual portion of BLOOD that is left after removal of BLOOD CELLS by CENTRIFUGATION without prior BLOOD COAGULATION.
The use of HIGH-ENERGY SHOCK WAVES, in the frequency range of 20-30 kHz, to cut through mineralized tissue.
Removal of degenerated and necrotic epithelium and underlying connective tissue of a periodontal pocket in an effort to convert a chronic ulcerated wound to an acute surgical wound, thereby insuring wound healing and attachment or epithelial adhesion, and shrinkage of the marginal gingiva. The term is sometimes used in connection with smoothing of a root surface or ROOT PLANING. (Jablonski; Illustrated Dictionary of Dentistry, 1982)
The process by which blood or its components are kept viable outside of the organism from which they are derived (i.e., kept from decay by means of a chemical agent, cooling, or a fluid substitute that mimics the natural state within the organism).
Testing erythrocytes to determine presence or absence of blood-group antigens, testing of serum to determine the presence or absence of antibodies to these antigens, and selecting biocompatible blood by crossmatching samples from the donor against samples from the recipient. Crossmatching is performed prior to transfusion.
The cells found in the body fluid circulating throughout the CARDIOVASCULAR SYSTEM.
Lasers which use a solid, as opposed to a liquid or gas, as the lasing medium. Common materials used are crystals, such as YAG (YTTRIUM aluminum garnet); alexandrite; and CORUNDUM, doped with a rare earth element such as a NEODYMIUM; ERBIUM; or HOLMIUM. The output is sometimes additionally modified by addition of non-linear optical materials such as potassium titanyl phosphate crystal, which for example is used with neodymium YAG lasers to convert the output light to the visible range.
Separation of one or more kinds of cells from whole blood with the return of other blood cell constituents to the patient or donor. This is accomplished with an instrument that uses centrifugation to separate the cells into different layers based on the differences in cell density (displacement) or drag coefficients in a current (elutriation). The procedure is commonly used in adoptive transfer to isolate NK cells, lymphocytes, or monocytes.
An antigenic mismatch between donor and recipient blood. Antibodies present in the recipient's serum may be directed against antigens in the donor product. Such a mismatch may result in a transfusion reaction in which, for example, donor blood is hemolyzed. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984).
The body fluid that circulates in the vascular system (BLOOD VESSELS). Whole blood includes PLASMA and BLOOD CELLS.
The fraction of a blood sample, following CENTRIFUGATION, that is distinguished as a thin light-colored layer between the RED BLOOD CELLS, underneath it, and the PLASMA, above it. It is composed mostly of WHITE BLOOD CELLS and PLATELETS.
A health professional's obligation to breach patient CONFIDENTIALITY to warn third parties of the danger of their being assaulted or of contracting a serious infection.
A legal requirement that designated types of information acquired by professionals or institutions in the course of their work be reported to appropriate authorities.
Adherent debris produced when cutting the enamel or dentin in cavity preparation. It is about 1 micron thick and its composition reflects the underlying dentin, although different quantities and qualities of smear layer can be produced by the various instrumentation techniques. Its function is presumed to be protective, as it lowers dentin permeability. However, it masks the underlying dentin and interferes with attempts to bond dental material to the dentin.
A myodegeneration most frequent in calves and lambs whose dams have been fed during gestation or longer on feeds, especially legumes (FABACEAE), grown in certain areas where selenium is either deficient or unavailable in the soil. It has been recorded in many countries. It has been produced experimentally in several species of animals on low-selenium intake. A similar myopathy occurs naturally in goats, deer, foals, and dogs but proof of the etiology is lacking. (Merck Veterinary Manual, 5th ed)
The preparation of platelet concentrates with the return of red cells and platelet-poor plasma to the donor.
An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.
The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES.
Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions.
The volume of packed RED BLOOD CELLS in a blood specimen. The volume is measured by centrifugation in a tube with graduated markings, or with automated blood cell counters. It is an indicator of erythrocyte status in disease. For example, ANEMIA shows a low value; POLYCYTHEMIA, a high value.
Antibodies from an individual that react with ISOANTIGENS of another individual of the same species.
Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN.
Erythrocyte isoantigens of the Rh (Rhesus) blood group system, the most complex of all human blood groups. The major antigen Rh or D is the most common cause of erythroblastosis fetalis.
The part of a tooth from the neck to the apex, embedded in the alveolar process and covered with cementum. A root may be single or divided into several branches, usually identified by their relative position, e.g., lingual root or buccal root. Single-rooted teeth include mandibular first and second premolars and the maxillary second premolar teeth. The maxillary first premolar has two roots in most cases. Maxillary molars have three roots. (Jablonski, Dictionary of Dentistry, 1992, p690)
Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation.
A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).
Data processing largely performed by automatic means.
The oxygen-carrying proteins of ERYTHROCYTES. They are found in all vertebrates and some invertebrates. The number of globin subunits in the hemoglobin quaternary structure differs between species. Structures range from monomeric to a variety of multimeric arrangements.
The transmission of infectious disease or pathogens. When transmission is within the same species, the mode can be horizontal or vertical (INFECTIOUS DISEASE TRANSMISSION, VERTICAL).
White blood cells. These include granular leukocytes (BASOPHILS; EOSINOPHILS; and NEUTROPHILS) as well as non-granular leukocytes (LYMPHOCYTES and MONOCYTES).
Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.

Infection of apheresis cells by parvovirus B19. (1/271)

Parvovirus B19 is the only member of the Parvoviridae family known to cause disease in humans. Owing to the high level of cell tropism the virus can only replicate in proliferating and differentiating erythroid precursor cells, which are present in human bone marrow and foetal liver. As human bone marrow is very difficult to obtain, an alternative in vitro system for the propagation of B19 virus has been developed, based on the application of mobilized haemapoietic progenitor (apheresis) cells. These cells are routinely harvested from cancer patients after treatment with recombinant human granulocyte/macrophage colony-stimulating factor. Replication of parvovirus B19 in vitro is possible in these cells after stimulation with erythropoietin. Therefore, this system is an easily, accessible alternative to the use of human bone marrow in parvovirus B19 infection assays.  (+info)

CD34+ cell enumeration in peripheral blood and apheresis samples, using two laboratory diagnostic kits or an institutional protocol. (2/271)

In order to prepare the substitution of a commercially available diagnostic kit, ProCOUNT (Becton Dickinson) or Stem-Kit (Coulter Immunotech), for our institutional protocol, we compared the three techniques for the numeration of CD34+ progenitor cells in 50 peripheral blood and 51 apheresis samples, obtained from cancer patients or healthy donors. We show here that the three techniques yield results of the same order of magnitude. Although statistical analyses demonstrate significant differences between the three methods, these differences turned out to be clinically insignificant in most situations. Observed differences mostly affect samples with the highest content of CD34+ cells, while the three assays provide equivalent results for values that are close to clinically relevant thresholds (20 x 10(3) CD34+ cells/ml in peripheral blood to start apheresis, and accumulated number above 3 x 10(6) CD34+ cells/kg to stop apheresis). This study also supports the view that institutional protocols can provide a highly reliable determination of CD34+ cells counts and percentages. However, because institutional protocols often use research reagents and vary from institution to institution, the use of diagnostic kits may be prefered as one way to improve quality assurance in the practice of cell therapy.  (+info)

Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens. (3/271)

The study purpose was to determine if G-CSF plus dose-intensive cyclophosphamide 5.25 g/m2, etoposide 1.05 g/m2 and cisplatin 105 mg/m2 (DICEP) results in superior autologous blood stem cell mobilization (BSCM) than less intensive chemotherapy. From January 1993 until May 1997, 152 consecutive patients with non-Hodgkin's lymphoma (n = 55), breast cancer (n = 47), Hodgkin's disease (n = 14), multiple myeloma (n = 9), AML (n = 9), or other cancers (n = 18) initially underwent BSCM by one of three methods: Group 1: G-CSF alone x 4 days (n = 30). Group 2: disease-oriented chemotherapy, dosed to avoid blood transfusions, followed by G-CSF starting day 7 or 8, and apheresis day 13 or 14 (n = 82). Group 3: DICEP days 1-3, G-CSF starting day 14, and apheresis planned day 19, 20 or 21 (n = 40). A multivariate analysis was performed to determine which factors independently predicted BSCM. The median peripheral blood CD34+ (PB CD34+) cell count the morning of apheresis linearly correlated with the number of CD34+ cells removed per litre of apheresis that day. The median PB CD34+ cell count and median CD34+ cells x 10(6) removed per litre of apheresis were highest for Group 3, intermediate for Group 2, and lowest for Group 1. By multivariate analysis, mobilization group (3 > 2 > 1), disease other than AML, no prior melphalan or mitomycin-C, and less than two prior chemotherapy regimens predicted better BSCM. Out of 15 Group 3 patients who had infiltrated marrows, 11 had no detectable cancer in marrow and apheresis products after DICEP. These data suggest that DICEP results in superior BSCM than less intensive chemotherapy regimens.  (+info)

Image-guided central venous catheters for apheresis. (4/271)

Apheresis is an increasingly important procedure in the treatment of a variety of conditions, sometimes performed via peripheral access because of concern over major complications associated with central venous catheter (CVC) placement. This study sought to determine the safety and success for ultrasound and fluoroscopically guided, non-tunneled dual lumen CVCs placed for apheresis. Prospective data collection was made of 200 attempted CVC placements in the radiology department utilizing real time sonographic guidance. The complications relating to placement were noted in all and the number of passes required for venepuncture and whether a single wall puncture was achieved was recorded in 185 cases. Duration of catheterization and reason for line removal were recorded in all. Our study group included 71 donors providing peripheral blood stem cells for allogeneic transplant. CVCs were successfully placed in all patients, 191 lines in the internal jugular and seven in the femoral vein. 86.5% required only a single pass and 80.5% with only anterior wall puncture. Inadvertent but clinically insignificant arterial puncture occurred in six (3%) cases. In no case did this prevent line placement. There were no other procedure-related complications. 173 (87.4%) catheters were removed the same day. No catheters were removed prematurely. There was one case of prolonged venous bleeding. Our study demonstrates the safety of central venous catheters for apheresis provided that duration of catheterization is short and real-time sonographic guidance is used for the puncture, and guide wire and catheter placement are confirmed fluoroscopically.  (+info)

Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. (5/271)

Lineage-specific growth factors mobilize peripheral blood progenitor cells (PBPC) and accelerate hematopoietic recovery after high-dose chemotherapy. Recombinant human thrombopoietin (rhTPO) may further increase the progenitor-cell content and regenerating potential of PBPC products. We evaluated the safety and activity of rhTPO as a PBPC mobilizer in combination with granulocyte colony-stimulating factor (G-CSF) in 29 breast cancer patients treated with high-dose chemotherapy followed by PBPC reinfusion. Initially, patients received escalating single doses of rhTPO intravenously (IV) at 0.6, 1.2, or 2.4 micrograms/kg, on day 1. Subsequent patients received rhTPO 0.6 or 0.3 micrograms/kg on days -3, -1, and 1, or 0.6 micrograms/kg on days -1 and 1. G-CSF, 5 micrograms/kg IV or subcutaneously (SC) twice daily, was started on day 3 and continued through aphereses. Twenty comparable, concurrently and identically treated patients (who were eligible and would have been treated on protocol but for the lack of study opening) mobilized with G-CSF alone served as comparisons. CD34(+) cell yields were substantially higher with the first apheresis following rhTPO and G-CSF versus G-CSF alone: 4.1 x 10(6)/kg (range, 1.3 to 17.6) versus 0.8 x 10(6)/ kg (range, 0.3 to 4.2), P =.0003. The targeted minimum yield of 3 x 10(6) CD34(+) cells/kg was procured following a single apheresis procedure in 61% of the rhTPO and G-CSF-mobilized group versus 10% of G-CSF-mobilized patients (P =.001). In rhTPO and G-CSF mobilized patients, granulocyte (day 8 v 9, P =.0001) and platelet recovery (day 9 v 10, P =.07) were accelerated, and fewer erythrocyte (3 v 4, P =.02) and platelet (4 v 5, P =.02) transfusions were needed compared with G-CSF-mobilized patients. Peripheral blood platelet counts, following rhTPO and G-CSF, were increased by greater than 100% and the platelet content of PBPC products by 60% to 110% on the first and second days of aphereses (P <.0001) with the greatest effect seen with repeated dosing of rhTPO at 0.6 microgram/kg. rhTPO is safe and well tolerated as a mobilizing agent before PBPC collection. Mobilization with rhTPO and G-CSF, in comparison to a comparable, nonrandomized G-CSF-mobilized group of patients, decreases the number of apheresis procedures required, may accelerate hematopoietic recovery, and may reduce the number of transfusions required following high-dose chemotherapy for breast cancer.  (+info)

Potential role for hyaluronan and the hyaluronan receptor RHAMM in mobilization and trafficking of hematopoietic progenitor cells. (6/271)

Although the mechanism(s) underlying mobilization of hematopoietic progenitor cells (HPCs) is unknown, detachment from the bone marrow (BM) microenvironment and motility are likely to play a role. This work analyzes the motile behavior of HPCs and the receptors involved. CD34(+)45(lo/med)Scatterlo/med HPCs from granulocyte colony-stimulating factor (G-CSF)-mobilized blood and mobilized BM were compared with steady-state BM for their ability to bind hyaluronan (HA), their expression of the HA receptors RHAMM and CD44, and their motogenic behavior. Although RHAMM and CD44 are expressed by mobilized blood HPCs, function blocking monoclonal antibodies (MoAbs) identified RHAMM as a major HA binding receptor, with a less consistent participation by CD44. Permeabilization of mobilized blood HPCs showed a pool of intracellular (ic) RHAMM and a smaller pool of icCD44. In contrast, steady-state BM HPCs have significantly larger pools of icRHAMM and icCD44. Also, in contrast to mobilized blood HPCs, for steady-state BM HPCs, MoAbs to RHAMM and CD44 act as agonists to upregulate HA binding. The comparison between mobilized and steady-state BM HPCs suggests that G-CSF mobilization is associated with depletion of intracellular stores of HA receptors and modulates HA receptor usage. To confirm that mobilization alters the HA receptor distribution and usage by HPCs, samples of BM were collected at the peak of G-CSF mobilization in parallel with mobilized blood samples. HA receptor distribution of mobilized BM HPCs was closely matched with mobilized blood HPCs and different from steady-state BM HPCs. Mobilized BM HPCs had lower pools of icHA receptors, similar to those of mobilized blood HPCs. Treatment of mobilized BM HPCs with anti-RHAMM MoAb decreased HA binding, in contrast to steady-state BM HPCs. Thus, G-CSF mobilization may stimulate an autocrine stimulatory loop for HPCs in which HA interacts with basal levels of RHAMM and/or CD44 to stimulate receptor recycling. Consistent with this, treatment of HPCs with azide, nystatin, or cytochalasin B increased HA binding, implicating an energy-dependent process involving lipid rafts and the cytoskeleton. Of the sorted HPCs, 66% were adherent and 27% were motile on fibronectin plus HA. HPC adherence was inhibited by MoAbs to beta1 integrin and CD44, but not to RHAMM, whereas HPC motility was inhibited by MoAb to RHAMM and beta1 integrin, but not to CD44. This finding suggests that RHAMM and CD44 play reciprocal roles in adhesion and motility by HPCs. The G-CSF-associated alterations in RHAMM distribution and the RHAMM-dependent motility of HPCs suggest a potential role for HA and RHAMM in trafficking of HPCs and the possible use of HA as a mobilizing agent in vivo.  (+info)

Autoaggression syndrome resembling acute graft-versus-host disease grade IV after autologous peripheral blood stem cell transplantation for breast cancer. (7/271)

Acute graft-versus-host disease (aGVHD) after autologous progenitor cell transplantation has been associated with blood transfusion or cyclosporine. Mild aGVHD grades I-II, identified as autoaggression or engraftment syndrome, has recently been described in autologous progenitor transplantation. Here, we report the first case of pathologically documented grade IV aGVHD after autologous peripheral blood progenitor cell transplantation in a patient with breast cancer. The allogeneic origin was excluded by molecular techniques, and no cyclosporine or cytokines were administered.  (+info)

Enrichment of peripheral blood CD34+ cells for transplantation using a fully automated immunomagnetic cell selection system and a novel octapeptide releasing agent. (8/271)

Positive selection of CD34+ cells is being increasingly performed to support hematological reconstitution following high-dose and dose-intensive chemotherapy and to reduce the non-target cell content of transplants. The present study was designed to evaluate the performance of an immunomagnetic cell selection system, including comparison of enzyme and peptide releasing agents and of semi-automated and fully automated selection systems. A total of 74 immunomagnetic CD34+ cell selection procedures were performed involving 55 subjects, the majority of whom had hematologic malignancies. Median CD34+ cell purity with a newly developed specific octapeptide releasing agent (98.5%; 81.0-99.0%) was significantly higher (P = 0.002) than that with chymopapain (85.8%; 28.1-99.7%). No significant differences were observed between semi-automated and fully automated systems in CD34+ cell purity or yield or time to WBC or platelet recovery. Immunomagnetic selection was found to provide highly purified populations of CD34+ cells in sufficient numbers for use in transplantation procedures. CD34+ cell transplants supported rapid and reliable hematologic reconstitution. Use of a fully automated system markedly reduced the time and labor required for immunomagnetic selection, potentially affording more standardized and reproducible positive selection of CD34+ cells.  (+info)

Blood component removal, also known as blood component therapy or apheresis, is a medical procedure that involves separating and removing specific components of the blood, such as red blood cells, white blood cells, platelets, or plasma, while returning the remaining components back to the donor or patient. This process can be used for therapeutic purposes, such as in the treatment of certain diseases and conditions, or for donation, such as in the collection of blood products for transfusion. The specific method and equipment used to perform blood component removal may vary depending on the intended application and the particular component being removed.

A blood component transfusion is the process of transferring a specific component of donated blood into a recipient's bloodstream. Blood components include red blood cells, plasma, platelets, and cryoprecipitate (a fraction of plasma that contains clotting factors). These components can be separated from whole blood and stored separately to allow for targeted transfusions based on the individual needs of the patient.

For example, a patient who is anemic may only require a red blood cell transfusion, while a patient with severe bleeding may need both red blood cells and plasma to replace lost volume and clotting factors. Platelet transfusions are often used for patients with low platelet counts or platelet dysfunction, and cryoprecipitate is used for patients with factor VIII or fibrinogen deficiencies.

Blood component transfusions must be performed under strict medical supervision to ensure compatibility between the donor and recipient blood types and to monitor for any adverse reactions. Proper handling, storage, and administration of blood components are also critical to ensure their safety and efficacy.

A blood bank is a facility that collects, tests, stores, and distributes blood and blood components for transfusion purposes. It is a crucial part of the healthcare system, as it ensures a safe and adequate supply of blood products to meet the needs of patients undergoing various medical procedures or treatments. The term "blood bank" comes from the idea that collected blood is "stored" or "banked" until it is needed for transfusion.

The primary function of a blood bank is to ensure the safety and quality of the blood supply. This involves rigorous screening and testing of donated blood to detect any infectious diseases, such as HIV, hepatitis B and C, syphilis, and West Nile virus. Blood banks also perform compatibility tests between donor and recipient blood types to minimize the risk of transfusion reactions.

Blood banks offer various blood products, including whole blood, red blood cells, platelets, plasma, and cryoprecipitate. These products can be used to treat a wide range of medical conditions, such as anemia, bleeding disorders, cancer, and trauma. In addition, some blood banks may also provide specialized services, such as apheresis (a procedure that separates specific blood components) and therapeutic phlebotomy (the removal of excess blood).

Blood banks operate under strict regulations and guidelines to ensure the safety and quality of their products and services. These regulations are established by national and international organizations, such as the American Association of Blood Banks (AABB), the World Health Organization (WHO), and the U.S. Food and Drug Administration (FDA).

A blood transfusion is a medical procedure in which blood or its components are transferred from one individual (donor) to another (recipient) through a vein. The donated blood can be fresh whole blood, packed red blood cells, platelets, plasma, or cryoprecipitate, depending on the recipient's needs. Blood transfusions are performed to replace lost blood due to severe bleeding, treat anemia, support patients undergoing major surgeries, or manage various medical conditions such as hemophilia, thalassemia, and leukemia. The donated blood must be carefully cross-matched with the recipient's blood type to minimize the risk of transfusion reactions.

A platelet transfusion is the process of medically administering platelets, which are small blood cells that help your body form clots to stop bleeding. Platelet transfusions are often given to patients with low platelet counts or dysfunctional platelets due to various reasons such as chemotherapy, bone marrow transplantation, disseminated intravascular coagulation (DIC), and other medical conditions leading to increased consumption or destruction of platelets. This procedure helps to prevent or treat bleeding complications in these patients. It's important to note that platelet transfusions should be given under the supervision of a healthcare professional, taking into account the patient's clinical condition, platelet count, and potential risks associated with transfusion reactions.

A blood donor is a person who voluntarily gives their own blood or blood components to be used for the benefit of another person in need. The blood donation process involves collecting the donor's blood, testing it for infectious diseases, and then storing it until it is needed by a patient. There are several types of blood donations, including:

1. Whole blood donation: This is the most common type of blood donation, where a donor gives one unit (about 450-500 milliliters) of whole blood. The blood is then separated into its components (red cells, plasma, and platelets) for transfusion to patients with different needs.
2. Double red cell donation: In this type of donation, the donor's blood is collected using a special machine that separates two units of red cells from the whole blood. The remaining plasma and platelets are returned to the donor during the donation process. This type of donation can be done every 112 days.
3. Platelet donation: A donor's blood is collected using a special machine that separates platelets from the whole blood. The red cells and plasma are then returned to the donor during the donation process. This type of donation can be done every seven days, up to 24 times a year.
4. Plasma donation: A donor's blood is collected using a special machine that separates plasma from the whole blood. The red cells and platelets are then returned to the donor during the donation process. This type of donation can be done every 28 days, up to 13 times a year.

Blood donors must meet certain eligibility criteria, such as being in good health, aged between 18 and 65 (in some countries, the upper age limit may vary), and weighing over 50 kg (110 lbs). Donors are also required to answer medical questionnaires and undergo a mini-physical examination before each donation. The frequency of blood donations varies depending on the type of donation and the donor's health status.

An erythrocyte transfusion, also known as a red blood cell (RBC) transfusion, is the process of transferring compatible red blood cells from a donor to a recipient. This procedure is typically performed to increase the recipient's oxygen-carrying capacity, usually in situations where there is significant blood loss, anemia, or impaired red blood cell production.

During the transfusion, the donor's red blood cells are collected, typed, and tested for compatibility with the recipient's blood to minimize the risk of a transfusion reaction. Once compatible units are identified, they are infused into the recipient's circulation through a sterile intravenous (IV) line. The recipient's body will eventually eliminate the donated red blood cells within 100-120 days as part of its normal turnover process.

Erythrocyte transfusions can be lifesaving in various clinical scenarios, such as trauma, surgery, severe anemia due to chronic diseases, and hematologic disorders. However, they should only be used when necessary, as there are potential risks associated with the procedure, including allergic reactions, transmission of infectious diseases, transfusion-related acute lung injury (TRALI), and iron overload in cases of multiple transfusions.

Leukocyte reduction procedures are medical processes that aim to decrease the number of white blood cells (leukocytes) in a unit of blood or blood component, such as red blood cells or platelets. These procedures are often used during transfusions for patients who have heightened reactions to leukocytes, or to lower the risk of complications like febrile non-hemolytic transfusion reactions, allergic reactions, and transmission of certain infectious agents.

The most common method for leukocyte reduction is filtration, where the blood component passes through a specialized filter that captures and removes the white blood cells. This process can reduce the leukocyte count to less than 1 x 10^6 per unit, which is significantly lower than the typical 5-10 x 10^6 leukocytes per unit found in unprocessed components.

Leukocyte reduction procedures are beneficial for specific patient populations, such as those undergoing chemotherapy or bone marrow transplantation, and help improve overall transfusion safety and efficacy.

In the context of medicine, plasma refers to the clear, yellowish fluid that is the liquid component of blood. It's composed of water, enzymes, hormones, antibodies, clotting factors, and other proteins. Plasma serves as a transport medium for cells, nutrients, waste products, gases, and other substances throughout the body. Additionally, it plays a crucial role in the immune response and helps regulate various bodily functions.

Plasma can be collected from blood donors and processed into various therapeutic products, such as clotting factors for people with hemophilia or immunoglobulins for patients with immune deficiencies. This process is called plasma fractionation.

Piezosurgery is a type of surgical procedure that uses ultrasonic vibrations to cut through bone tissue while minimizing damage to surrounding soft tissues. It is often used in oral and maxillofacial surgery, such as during dental implant placement or jaw osteotomies. The piezoelectric instrument generates high-frequency microvibrations that selectively cut mineralized tissue like bone, while leaving adjacent soft tissues largely unaffected. This allows for precise cuts with less trauma and bleeding compared to traditional surgical techniques, potentially resulting in faster healing times and reduced postoperative discomfort.

Subgingival curettage is a dental procedure that involves the removal of infected tissue from the area below the gum line (subgingival) down to the bottom of the periodontal pocket. This procedure is typically performed by a dentist or dental hygienist during a deep cleaning or scaling and root planing procedure to treat periodontal disease. The goal of subgingival curettage is to remove damaged, infected, or necrotic tissue from the periodontal pocket, which can help promote healing and reduce the depth of the pocket. This procedure may also be used as a diagnostic tool to assess the extent of periodontal damage and guide treatment planning.

Blood preservation refers to the process of keeping blood viable and functional outside of the body for transfusion purposes. This is typically achieved through the addition of various chemical additives, such as anticoagulants and nutrients, to a storage solution in which the blood is contained. The preserved blood is then refrigerated or frozen until it is needed for transfusion.

The goal of blood preservation is to maintain the structural integrity and functional capacity of the red blood cells, white blood cells, and platelets, as well as the coagulation factors, in order to ensure that the transfused blood is safe and effective. Different storage conditions and additives are used for the preservation of different components of blood, depending on their specific requirements.

It's important to note that while blood preservation extends the shelf life of donated blood, it does not last indefinitely. The length of time that blood can be stored depends on several factors, including the type of blood component and the storage conditions. Regular testing is performed to ensure that the preserved blood remains safe and effective for transfusion.

Blood grouping, also known as blood typing, is the process of determining a person's ABO and Rh (Rhesus) blood type. The ABO blood group system includes four main blood types: A, B, AB, and O, based on the presence or absence of antigens A and B on the surface of red blood cells. The Rh blood group system is another important classification system that determines whether the Rh factor (a protein also found on the surface of red blood cells) is present or absent.

Knowing a person's blood type is crucial in transfusion medicine to ensure compatibility between donor and recipient blood. If a patient receives an incompatible blood type, it can trigger an immune response leading to serious complications such as hemolysis (destruction of red blood cells), kidney failure, or even death.

Crossmatching is a laboratory test performed before a blood transfusion to determine the compatibility between the donor's and recipient's blood. It involves mixing a small sample of the donor's red blood cells with the recipient's serum (the liquid portion of the blood containing antibodies) and observing for any agglutination (clumping) or hemolysis. If there is no reaction, the blood is considered compatible, and the transfusion can proceed.

In summary, blood grouping and crossmatching are essential tests in transfusion medicine to ensure compatibility between donor and recipient blood and prevent adverse reactions that could harm the patient's health.

Blood cells are the formed elements in the blood, including red blood cells (erythrocytes), white blood cells (leukocytes), and platelets (thrombocytes). These cells are produced in the bone marrow and play crucial roles in the body's functions. Red blood cells are responsible for carrying oxygen to tissues and carbon dioxide away from them, while white blood cells are part of the immune system and help defend against infection and disease. Platelets are cell fragments that are essential for normal blood clotting.

Solid-state lasers are a type of laser that uses solid materials as the gain medium – the material that amplifies the light energy to produce laser emissions. In contrast to gas or liquid lasers, solid-state lasers use a crystal, ceramic, or glass as the gain medium. The active laser medium in solid-state lasers is typically doped with rare earth ions, such as neodymium (Nd), yttrium (Y), erbium (Er), or thulium (Tm).

The most common type of solid-state laser is the neodymium-doped yttrium aluminum garnet (Nd:YAG) laser. In this laser, neodymium ions are doped into a crystal lattice made up of yttrium, aluminum, and garnet (YAG). The Nd:YAG laser emits light at a wavelength of 1064 nanometers (nm), which can be frequency-doubled to produce emissions at 532 nm.

Solid-state lasers have several advantages over other types of lasers, including high efficiency, long lifetimes, and compact size. They are widely used in various applications, such as material processing, medical treatments, scientific research, and military technology.

Cytapheresis is a medical procedure that involves the separation and removal of specific types of blood cells or particles from a donor or patient's blood, while returning the remaining components back to the circulation. The term "cytapheresis" comes from the Greek words "kytos," meaning cell, and "apherein," meaning to transfer or remove.

There are several types of cytapheresis, including:

1. Erythrocytapheresis (Red Cell Exchange): This procedure is used to reduce the number of red blood cells in patients with severe sickle cell disease or other hemoglobinopathies during a vaso-occlusive crisis or to prevent stroke in children with sickle cell disease.
2. Leukapheresis: It is used to collect large numbers of white blood cells (leukocytes) from donors for the production of immunotherapeutic agents, such as monoclonal antibodies and dendritic cell vaccines. Additionally, it can be employed to reduce the number of white blood cells in patients with leukemia or other hematological disorders.
3. Plateletapheresis: This procedure is used to collect platelets from donors for transfusion purposes or to reduce the number of platelets in patients with thrombocytopenia or thrombocytosis.
4. Lymphapheresis: It is used to collect lymphocytes, mainly T- and B-cells, from donors for immunotherapy or to deplete malignant lymphocytes in patients with certain types of cancer, such as Hodgkin's lymphoma.
5. Lipoproteinapheresis: This procedure is used to lower the levels of low-density lipoproteins (LDL) and lipids in patients with familial hypercholesterolemia or other severe forms of dyslipidemia.

Cytapheresis can be performed using a centrifugation method, where blood is spun in a special machine to separate the components based on their density, or a filtration method, where blood passes through a filter that captures the target cells or particles. The procedure typically takes 1-3 hours and may require the use of anticoagulants to prevent clotting during the process.

Blood group incompatibility refers to a situation where the blood type of a donor and a recipient are not compatible, leading to an immune response and destruction of the donated red blood cells. This is because the recipient's immune system recognizes the donor's red blood cells as foreign due to the presence of incompatible antigens on their surface.

The most common type of blood group incompatibility occurs between individuals with different ABO blood types, such as when a person with type O blood receives type A, B, or AB blood. This can lead to agglutination and hemolysis of the donated red blood cells, causing potentially life-threatening complications such as hemolytic transfusion reaction.

Another type of blood group incompatibility occurs between Rh-negative mothers and their Rh-positive fetuses. If a mother's immune system is exposed to her fetus's Rh-positive red blood cells during pregnancy or childbirth, she may develop antibodies against them. This can lead to hemolytic disease of the newborn if the mother becomes pregnant with another Rh-positive fetus in the future.

To prevent these complications, it is essential to ensure that donated blood is compatible with the recipient's blood type before transfusion and that appropriate measures are taken during pregnancy and childbirth to prevent sensitization of Rh-negative mothers to Rh-positive red blood cells.

Blood is the fluid that circulates in the body of living organisms, carrying oxygen and nutrients to the cells and removing carbon dioxide and other waste products. It is composed of red and white blood cells suspended in a liquid called plasma. The main function of blood is to transport oxygen from the lungs to the body's tissues and carbon dioxide from the tissues to the lungs. It also transports nutrients, hormones, and other substances to the cells and removes waste products from them. Additionally, blood plays a crucial role in the body's immune system by helping to fight infection and disease.

The term "blood buffy coat" is not a standard medical terminology, but it is used in the field of laboratory medicine and hematology. The "buffy coat" refers to the thin layer of white blood cells (leukocytes) and platelets (thrombocytes) that can be seen when a sample of anticoagulated whole blood is centrifuged, causing the red blood cells (erythrocytes) to settle at the bottom and the plasma to form a layer on top. The buffy coat is located in between these two layers.

The term "blood buffy coat" may refer to the process of collecting this thin layer of white blood cells and platelets for further analysis, such as during a complete blood count (CBC) or other diagnostic tests. It can also refer to a sample that has been prepared in this way, where the buffy coat is concentrated and visible for examination under a microscope.

Abnormalities in the appearance or composition of the buffy coat may indicate various medical conditions, such as leukemia, infection, inflammation, or other hematological disorders.

The "duty to warn" is a legal and ethical obligation that healthcare professionals have to inform their patients or others who may be at risk of harm from the actions or behaviors of their patient. This duty arises from the principle of non-maleficence, which requires doctors to avoid causing harm to their patients.

In the context of medical practice, the duty to warn typically applies when a patient has a mental illness or condition that makes them a danger to themselves or others. For example, if a psychiatrist determines that their patient poses a serious threat of violence to a specific individual, they may have a legal and ethical obligation to warn that person or take other steps to protect them from harm.

The specifics of the duty to warn can vary depending on the jurisdiction and the circumstances involved. In some cases, healthcare professionals may be required to report certain types of threats or behaviors to law enforcement authorities. Ultimately, the goal of the duty to warn is to prevent harm and promote the safety and well-being of patients and others who may be at risk.

Mandatory reporting is a legal requirement that healthcare professionals, as well as other designated individuals or organizations, must report suspected or confirmed cases of abuse, neglect, or exploitation of vulnerable populations to the appropriate authorities. These vulnerable populations often include children, elderly persons, and individuals with disabilities. The purpose of mandatory reporting is to ensure the protection and safety of these at-risk individuals and to facilitate interventions that can address and prevent further harm.

Healthcare professionals who are mandated reporters typically include doctors, nurses, mental health professionals, social workers, and teachers, among others. Mandatory reporting requirements vary by jurisdiction but generally involve immediate notification upon suspicion or knowledge of maltreatment. Failing to report as required can result in legal consequences for the mandated reporter, including potential penalties such as fines, license suspension, or even criminal charges.

The specifics of mandatory reporting laws and regulations differ between countries, states, and provinces; therefore, it is essential for healthcare professionals to be familiar with the requirements applicable to their particular practice settings.

A smear layer is a thin, amorphous layer of debris that forms on the dentin surface when it comes into contact with instruments or solutions during dental procedures such as cavity preparation, root canal treatment, or biopsies. This layer is composed of organic and inorganic components, including dentinal cuttings, pulp tissue, bacteria, and materials from the irrigating solution. The smear layer can occlude the dentinal tubules, affecting the adhesion of filling materials and sealing ability of obturation points. Therefore, it is often removed during root canal preparation using various methods such as chemical dissolution, ultrasonic agitation, or laser ablation to ensure proper disinfection and seal of the root canal system.

White muscle disease is not a formal medical term, but it is a condition commonly referred to in veterinary medicine, particularly in the context of livestock and wildlife. It's also known as nutritional muscular dystrophy or enzootic muscular dystrophy.

The term "white muscle disease" refers to a group of conditions characterized by degeneration and necrosis (death) of skeletal and cardiac muscle tissue, primarily caused by deficiencies in certain nutrients, particularly selenium and vitamin E. These nutrients play crucial roles in the antioxidant defense system within the body, protecting cells from oxidative damage.

In affected animals, the lack of these essential nutrients leads to muscle damage, which can result in various clinical signs, such as:

1. Weakness
2. Stiffness
3. Reluctance to move
4. Difficulty swallowing or breathing (in severe cases)
5. Sudden death (often due to heart failure)

White muscle disease is most commonly observed in ruminants like cattle, sheep, and goats, as well as certain species of swine, poultry, and wild animals. It can be prevented through dietary supplementation with selenium and vitamin E or by providing these nutrients through mineral-rich soil and forage. In some cases, treatment may involve administering selenium and vitamin E injections to help support muscle recovery and prevent further damage.

Plateletpheresis is a medical procedure that involves the collection of platelets from a donor's blood through a process called apheresis. In this process, whole blood is withdrawn from the donor, and the platelets are separated from other blood components using a specialized machine. The separated platelets are then collected in a sterile bag, while the remaining blood components (red blood cells, white blood cells, and plasma) are returned to the donor's body.

Plateletpheresis is often used to collect platelets for transfusion purposes, particularly for patients who require large volumes of platelets due to conditions such as leukemia, aplastic anemia, or other forms of cancer. It is also used in the treatment of thrombocytopenia, a condition characterized by abnormally low levels of platelets in the blood.

The procedure typically takes between one to two hours and requires the use of a specialized machine and trained medical staff. Donors may experience mild side effects such as fatigue, bruising, or discomfort at the site where the needle was inserted, but serious complications are rare.

The United States Food and Drug Administration (FDA) is a federal government agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our country's food supply, cosmetics, and products that emit radiation. The FDA also provides guidance on the proper use of these products, and enforces laws and regulations related to them. It is part of the Department of Health and Human Services (HHS).

A "Blood Cell Count" is a medical laboratory test that measures the number of red blood cells (RBCs), white blood cells (WBCs), and platelets in a sample of blood. This test is often used as a part of a routine check-up or to help diagnose various medical conditions, such as anemia, infection, inflammation, and many others.

The RBC count measures the number of oxygen-carrying cells in the blood, while the WBC count measures the number of immune cells that help fight infections. The platelet count measures the number of cells involved in clotting. Abnormal results in any of these counts may indicate an underlying medical condition and further testing may be required for diagnosis and treatment.

Blood coagulation disorders, also known as bleeding disorders or clotting disorders, refer to a group of medical conditions that affect the body's ability to form blood clots properly. Normally, when a blood vessel is injured, the body's coagulation system works to form a clot to stop the bleeding and promote healing.

In blood coagulation disorders, there can be either an increased tendency to bleed due to problems with the formation of clots (hemorrhagic disorder), or an increased tendency for clots to form inappropriately even without injury, leading to blockages in the blood vessels (thrombotic disorder).

Examples of hemorrhagic disorders include:

1. Hemophilia - a genetic disorder that affects the ability to form clots due to deficiencies in clotting factors VIII or IX.
2. Von Willebrand disease - another genetic disorder caused by a deficiency or abnormality of the von Willebrand factor, which helps platelets stick together to form a clot.
3. Liver diseases - can lead to decreased production of coagulation factors, increasing the risk of bleeding.
4. Disseminated intravascular coagulation (DIC) - a serious condition where clotting and bleeding occur simultaneously due to widespread activation of the coagulation system.

Examples of thrombotic disorders include:

1. Factor V Leiden mutation - a genetic disorder that increases the risk of inappropriate blood clot formation.
2. Antithrombin III deficiency - a genetic disorder that impairs the body's ability to break down clots, increasing the risk of thrombosis.
3. Protein C or S deficiencies - genetic disorders that lead to an increased risk of thrombosis due to impaired regulation of the coagulation system.
4. Antiphospholipid syndrome (APS) - an autoimmune disorder where the body produces antibodies against its own clotting factors, increasing the risk of thrombosis.

Treatment for blood coagulation disorders depends on the specific diagnosis and may include medications to manage bleeding or prevent clots, as well as lifestyle changes and monitoring to reduce the risk of complications.

Hematocrit is a medical term that refers to the percentage of total blood volume that is made up of red blood cells. It is typically measured as part of a complete blood count (CBC) test. A high hematocrit may indicate conditions such as dehydration, polycythemia, or living at high altitudes, while a low hematocrit may be a sign of anemia, bleeding, or overhydration. It is important to note that hematocrit values can vary depending on factors such as age, gender, and pregnancy status.

Isoantibodies are antibodies produced by the immune system that recognize and react to antigens (markers) found on the cells or tissues of another individual of the same species. These antigens are typically proteins or carbohydrates present on the surface of red blood cells, but they can also be found on other cell types.

Isoantibodies are formed when an individual is exposed to foreign antigens, usually through blood transfusions, pregnancy, or tissue transplantation. The exposure triggers the immune system to produce specific antibodies against these antigens, which can cause a harmful immune response if the individual receives another transfusion or transplant from the same donor in the future.

There are two main types of isoantibodies:

1. Agglutinins: These are IgM antibodies that cause red blood cells to clump together (agglutinate) when mixed with the corresponding antigen. They develop rapidly after exposure and can cause immediate transfusion reactions or hemolytic disease of the newborn in pregnant women.
2. Hemolysins: These are IgG antibodies that destroy red blood cells by causing their membranes to become more permeable, leading to lysis (bursting) of the cells and release of hemoglobin into the plasma. They take longer to develop but can cause delayed transfusion reactions or hemolytic disease of the newborn in pregnant women.

Isoantibodies are detected through blood tests, such as the crossmatch test, which determines compatibility between a donor's and recipient's blood before transfusions or transplants.

Erythrocytes, also known as red blood cells (RBCs), are the most common type of blood cell in circulating blood in mammals. They are responsible for transporting oxygen from the lungs to the body's tissues and carbon dioxide from the tissues to the lungs.

Erythrocytes are formed in the bone marrow and have a biconcave shape, which allows them to fold and bend easily as they pass through narrow blood vessels. They do not have a nucleus or mitochondria, which makes them more flexible but also limits their ability to reproduce or repair themselves.

In humans, erythrocytes are typically disc-shaped and measure about 7 micrometers in diameter. They contain the protein hemoglobin, which binds to oxygen and gives blood its red color. The lifespan of an erythrocyte is approximately 120 days, after which it is broken down in the liver and spleen.

Abnormalities in erythrocyte count or function can lead to various medical conditions, such as anemia, polycythemia, and sickle cell disease.

The Rh-Hr blood group system is a complex system of antigens found on the surface of red blood cells (RBCs), which is separate from the more well-known ABO blood group system. The term "Rh" refers to the Rhesus monkey, as these antigens were first discovered in rhesus macaques.

The Rh system consists of several antigens, but the most important ones are the D antigen (also known as the Rh factor) and the hr/Hr antigens. The D antigen is the one that determines whether a person's blood is Rh-positive or Rh-negative. If the D antigen is present, the blood is Rh-positive; if it is absent, the blood is Rh-negative.

The hr/Hr antigens are less well known but can still cause problems in blood transfusions and pregnancy. The Hr antigen is relatively rare, found in only about 1% of the population, while the hr antigen is more common.

When a person with Rh-negative blood is exposed to Rh-positive blood (for example, through a transfusion or during pregnancy), their immune system may produce antibodies against the D antigen. This can cause problems if they later receive a transfusion with Rh-positive blood or if they become pregnant with an Rh-positive fetus.

The Rh-Hr blood group system is important in blood transfusions and obstetrics, as it can help ensure that patients receive compatible blood and prevent complications during pregnancy.

A tooth root is the part of a tooth that is embedded in the jawbone and cannot be seen when looking at a person's smile. It is the lower portion of a tooth that typically has a conical shape and anchors the tooth to the jawbone through a periodontal ligament. The tooth root is covered by cementum, a specialized bone-like tissue, and contains nerve endings and blood vessels within its pulp chamber.

The number of roots in a tooth can vary depending on the type of tooth. For example, incisors typically have one root, canines may have one or two roots, premolars usually have one or two roots, and molars often have two to four roots. The primary function of the tooth root is to provide stability and support for the crown of the tooth, allowing it to withstand the forces of biting and chewing.

Blood platelets, also known as thrombocytes, are small, colorless cell fragments in our blood that play an essential role in normal blood clotting. They are formed in the bone marrow from large cells called megakaryocytes and circulate in the blood in an inactive state until they are needed to help stop bleeding. When a blood vessel is damaged, platelets become activated and change shape, releasing chemicals that attract more platelets to the site of injury. These activated platelets then stick together to form a plug, or clot, that seals the wound and prevents further blood loss. In addition to their role in clotting, platelets also help to promote healing by releasing growth factors that stimulate the growth of new tissue.

Acute Lung Injury (ALI) is a medical condition characterized by inflammation and damage to the lung tissue, which can lead to difficulty breathing and respiratory failure. It is often caused by direct or indirect injury to the lungs, such as pneumonia, sepsis, trauma, or inhalation of harmful substances.

The symptoms of ALI include shortness of breath, rapid breathing, cough, and low oxygen levels in the blood. The condition can progress rapidly and may require mechanical ventilation to support breathing. Treatment typically involves addressing the underlying cause of the injury, providing supportive care, and managing symptoms.

In severe cases, ALI can lead to Acute Respiratory Distress Syndrome (ARDS), a more serious and life-threatening condition that requires intensive care unit (ICU) treatment.

Automatic Data Processing (ADP) is not a medical term, but a general business term that refers to the use of computers and software to automate and streamline administrative tasks and processes. In a medical context, ADP may be used in healthcare settings to manage electronic health records (EHRs), billing and coding, insurance claims processing, and other data-intensive tasks.

The goal of using ADP in healthcare is to improve efficiency, accuracy, and timeliness of administrative processes, while reducing costs and errors associated with manual data entry and management. By automating these tasks, healthcare providers can focus more on patient care and less on paperwork, ultimately improving the quality of care delivered to patients.

Hemoglobin (Hb or Hgb) is the main oxygen-carrying protein in the red blood cells, which are responsible for delivering oxygen throughout the body. It is a complex molecule made up of four globin proteins and four heme groups. Each heme group contains an iron atom that binds to one molecule of oxygen. Hemoglobin plays a crucial role in the transport of oxygen from the lungs to the body's tissues, and also helps to carry carbon dioxide back to the lungs for exhalation.

There are several types of hemoglobin present in the human body, including:

* Hemoglobin A (HbA): This is the most common type of hemoglobin, making up about 95-98% of total hemoglobin in adults. It consists of two alpha and two beta globin chains.
* Hemoglobin A2 (HbA2): This makes up about 1.5-3.5% of total hemoglobin in adults. It consists of two alpha and two delta globin chains.
* Hemoglobin F (HbF): This is the main type of hemoglobin present in fetal life, but it persists at low levels in adults. It consists of two alpha and two gamma globin chains.
* Hemoglobin S (HbS): This is an abnormal form of hemoglobin that can cause sickle cell disease when it occurs in the homozygous state (i.e., both copies of the gene are affected). It results from a single amino acid substitution in the beta globin chain.
* Hemoglobin C (HbC): This is another abnormal form of hemoglobin that can cause mild to moderate hemolytic anemia when it occurs in the homozygous state. It results from a different single amino acid substitution in the beta globin chain than HbS.

Abnormal forms of hemoglobin, such as HbS and HbC, can lead to various clinical disorders, including sickle cell disease, thalassemia, and other hemoglobinopathies.

Infectious disease transmission refers to the spread of an infectious agent or pathogen from an infected person, animal, or contaminated object to another susceptible host. This can occur through various routes, including:

1. Contact transmission: Direct contact with an infected person or animal, such as through touching, kissing, or sexual contact.
2. Droplet transmission: Inhalation of respiratory droplets containing the pathogen, which are generated when an infected person coughs, sneezes, talks, or breathes heavily.
3. Airborne transmission: Inhalation of smaller particles called aerosols that can remain suspended in the air for longer periods and travel farther distances than droplets.
4. Fecal-oral transmission: Consuming food or water contaminated with fecal matter containing the pathogen, often through poor hygiene practices.
5. Vector-borne transmission: Transmission via an intermediate vector, such as a mosquito or tick, that becomes infected after feeding on an infected host and then transmits the pathogen to another host during a subsequent blood meal.
6. Vehicle-borne transmission: Consuming food or water contaminated with the pathogen through vehicles like soil, water, or fomites (inanimate objects).

Preventing infectious disease transmission is crucial in controlling outbreaks and epidemics. Measures include good personal hygiene, vaccination, use of personal protective equipment (PPE), safe food handling practices, and environmental disinfection.

Leukocytes, also known as white blood cells (WBCs), are a crucial component of the human immune system. They are responsible for protecting the body against infections and foreign substances. Leukocytes are produced in the bone marrow and circulate throughout the body in the bloodstream and lymphatic system.

There are several types of leukocytes, including:

1. Neutrophils - These are the most abundant type of leukocyte and are primarily responsible for fighting bacterial infections. They contain enzymes that can destroy bacteria.
2. Lymphocytes - These are responsible for producing antibodies and destroying virus-infected cells, as well as cancer cells. There are two main types of lymphocytes: B-lymphocytes and T-lymphocytes.
3. Monocytes - These are the largest type of leukocyte and help to break down and remove dead or damaged tissues, as well as microorganisms.
4. Eosinophils - These play a role in fighting parasitic infections and are also involved in allergic reactions and inflammation.
5. Basophils - These release histamine and other chemicals that cause inflammation in response to allergens or irritants.

An abnormal increase or decrease in the number of leukocytes can indicate an underlying medical condition, such as an infection, inflammation, or a blood disorder.

A wound is a type of injury that occurs when the skin or other tissues are cut, pierced, torn, or otherwise broken. Wounds can be caused by a variety of factors, including accidents, violence, surgery, or certain medical conditions. There are several different types of wounds, including:

* Incisions: These are cuts that are made deliberately, often during surgery. They are usually straight and clean.
* Lacerations: These are tears in the skin or other tissues. They can be irregular and jagged.
* Abrasions: These occur when the top layer of skin is scraped off. They may look like a bruise or a scab.
* Punctures: These are wounds that are caused by sharp objects, such as needles or knives. They are usually small and deep.
* Avulsions: These occur when tissue is forcibly torn away from the body. They can be very serious and require immediate medical attention.

Injuries refer to any harm or damage to the body, including wounds. Injuries can range from minor scrapes and bruises to more severe injuries such as fractures, dislocations, and head trauma. It is important to seek medical attention for any injury that is causing significant pain, swelling, or bleeding, or if there is a suspected bone fracture or head injury.

In general, wounds and injuries should be cleaned and covered with a sterile bandage to prevent infection. Depending on the severity of the wound or injury, additional medical treatment may be necessary. This may include stitches for deep cuts, immobilization for broken bones, or surgery for more serious injuries. It is important to follow your healthcare provider's instructions carefully to ensure proper healing and to prevent complications.

Retrospective studies, also known as retrospective research or looking back studies, are a type of observational study that examines data from the past to draw conclusions about possible causal relationships between risk factors and outcomes. In these studies, researchers analyze existing records, medical charts, or previously collected data to test a hypothesis or answer a specific research question.

Retrospective studies can be useful for generating hypotheses and identifying trends, but they have limitations compared to prospective studies, which follow participants forward in time from exposure to outcome. Retrospective studies are subject to biases such as recall bias, selection bias, and information bias, which can affect the validity of the results. Therefore, retrospective studies should be interpreted with caution and used primarily to generate hypotheses for further testing in prospective studies.

A leukocyte count, also known as a white blood cell (WBC) count, is a laboratory test that measures the number of leukocytes in a sample of blood. Leukocytes are a vital part of the body's immune system and help fight infection and inflammation. A high or low leukocyte count may indicate an underlying medical condition, such as an infection, inflammation, or a bone marrow disorder. The normal range for a leukocyte count in adults is typically between 4,500 and 11,000 cells per microliter (mcL) of blood. However, the normal range can vary slightly depending on the laboratory and the individual's age and sex.

No FAQ available that match "blood component removal"

No images available that match "blood component removal"